Optonol Ltd.

Optonol (acquired by Alcon/Novartis) developed Ex-PressTM, a microscopic glaucoma shunt that is transforming glaucoma therapy globally on its way to becoming the gold standard in glaucoma surgery.



Medigus (TASE: MDGS) is developing endoscopy systems for the treatment of GERD (Gastro Esophageal Reflex Disease) and other diseases of the digestive system.



XTL (NASDAQ:XTLB; TASE: XTL) is developing therapeutics for the treatment of diabetic neuropathic pain and HCV.



ColBar (acquired by Johnson & Johnson) is a biomaterials company specializing in reconstructive medicine and tissue engineering.



NanoPass Technologies is a pioneer in the field of intradermal delivery of vaccines and large molecules (e.g. insulin). NanoPass Technologies developed MicronJetTM, a silicon-based micro-needle, the first and currently the only true intradermal (skin) delivery solution being commercialized for vaccines and large molecules.



ReWalk Robotics (NASDAQ: RWLK) is transforming the health and life experiences of people with spinal cord injuries. The ReWalk™, a robotic exoskeleton, enables paraplegics to restore walking in their daily lives. The ReWalk is the only exoskeleton approved by the FDA for personal use, and is marketed worldwide. 



Peri-Ness is a biotechnology company focusing on addressing the problem of male infertility. The company’s product is a systemic protein-based drug for treatment of male sub-fertility.



Invasix develops manufactures and sells semi-invasive and non-invasive products for aesthetic surgery. The company’s proprietary technology enables physicians to broaden their offering to potential patients, and deliver better results in shorter and simpler procedures.



HomeSkinovations develops, manufactures and sells advanced home-use aesthetic devices. HomeSkinovations revolutionized the medical esthetics market in 2008 by introducing the first pulsed-light technology in a medical esthetics device for home use. More than 2 million Silk’n® devices in various models have been sold worldwide, bringing in more than $100 million in sales in 2014.

Petnovation CatGenie


PetNovations’ mission statement is to revolutionize the current “low-tech” pet equipment market. The company is developing, manufacturing and marketing products that improve the life quality of pets and pet owners by introducing advanced, new-concept solutions to pet owners’ most basic unmet needs.

Gamida Cell


Gamida Cell (with Novartis recently joining as a strategic investor) is a world leader in stem-cell therapy products for transplantation and regenerative medicine. NiCord® is a breakthrough therapy for millions of patients with blood cancers, autoimmune diseases, and non-malignant hematological diseased, all currently with no other hope of a cure..

Easy Lap


EasyLap’s mission is to develop supporting, easy to use devices, which will simplify and shorten laparoscopic procedures, thus enabling more widespread use of this superior, yet not exploited, surgical technique.



D-Pharm (TASE: DPRM) discovers and develops lipid-based drugs for the treatment of central nervous system disorders and cancer. The Company has developed two unique platform technologies that generate lipid–like medicines which utilize lipid specific properties and lipid-related pathways in living cells.


Mazor Robotics

Mazor Robotics (NASDAQ:MZOR): RenaissanceTM, its robotic guidance system used worldwide in thousands of spine procedures, is transforming spinal surgery from freehand to highly accurate, state-of-the-art operations.



GI-View is introducing a new generation of endoscopy products for gastrointestinal applications based on unique visualization and self-propelled pneumatic intubation technology. The company’s flagship Aer-O-Scope™ Colonoscope is a disposable, self-propelled colonoscope incorporating a miniature 360° omni-directional camera and is CE and FDA-marked.



OrSense is a medical device company that develops and commercializes innovative non-invasive monitoring technologies for continuous and spot measurements of blood parameters.



Syneron (NASDAQ: ELOS) develops, manufactures and markets medical aesthetic devices based on the ELOS combined energy technology (Electro-Optical Synergy) using Bi-Polar Radio Frequency and Light. The company’s products have superior safety features comparing to other devices on the market, with equal or even better efficacy